TTNT analysis
| . | Median TTNT (mo) . | TTNT 95% CI (mo) . | 1-y free from further treatment (%) . | 2-y free from further treatment (%) . | Median line of therapy . |
|---|---|---|---|---|---|
| All treatments | 5.4 | 5.1-6.1 | 29.2 | 21.4 | 3 |
| Chemotherapy | 3.9 | 3.2-5.1 | 10.7 | 5.4 | 4 |
| α-interferon | 8.7 | 6.0-18.0 | 41.7 | 29.1 | 2 |
| HDACi | 4.5 | 4.0-6.1 | 20.0 | 14.5 | 3 |
| Bexarotene | 7.3 | 2.6-110.8 | 47.4 | 36.8 | 2 |
| Alemtuzumab | 4.1 | 2.7-6.5 | 27.8 | 27.8 | 3.5 |
| Denileukin diftitox | 5.1 | 2.7-6.5 | 22.7 | 22.7 | 4 |
| AuSCT | 7.8 | 4.7-24.4 | 41.5 | 28.4 | 3 |
| AlloSCT | 34.6 | 11.5-N/A | 80.0 | 53.3 | 6 |
| ECP | 9.2 | 5.9-12.8 | 39.1 | 25.7 | 2 |
| TSEB | 7.8 | 4.4-14.7 | 39.0 | 26.5 | 2 |
| Low-dose methotrexate | 5.0 | 3.6-6.5 | 25.1 | 21.2 | 2 |
| . | Median TTNT (mo) . | TTNT 95% CI (mo) . | 1-y free from further treatment (%) . | 2-y free from further treatment (%) . | Median line of therapy . |
|---|---|---|---|---|---|
| All treatments | 5.4 | 5.1-6.1 | 29.2 | 21.4 | 3 |
| Chemotherapy | 3.9 | 3.2-5.1 | 10.7 | 5.4 | 4 |
| α-interferon | 8.7 | 6.0-18.0 | 41.7 | 29.1 | 2 |
| HDACi | 4.5 | 4.0-6.1 | 20.0 | 14.5 | 3 |
| Bexarotene | 7.3 | 2.6-110.8 | 47.4 | 36.8 | 2 |
| Alemtuzumab | 4.1 | 2.7-6.5 | 27.8 | 27.8 | 3.5 |
| Denileukin diftitox | 5.1 | 2.7-6.5 | 22.7 | 22.7 | 4 |
| AuSCT | 7.8 | 4.7-24.4 | 41.5 | 28.4 | 3 |
| AlloSCT | 34.6 | 11.5-N/A | 80.0 | 53.3 | 6 |
| ECP | 9.2 | 5.9-12.8 | 39.1 | 25.7 | 2 |
| TSEB | 7.8 | 4.4-14.7 | 39.0 | 26.5 | 2 |
| Low-dose methotrexate | 5.0 | 3.6-6.5 | 25.1 | 21.2 | 2 |
AlloSCT, allogeneic hematopoietic SCT; N/A, not able to be assessed; TSEB, total skin electron beam radiation.